EsoCheck® / EsoGuard® System
Detection of Barrett's Esophagus and associated dysplasia in at-risk patients (e.g., chronic GERD)
CommercialActive, Commercially Available
Key Facts
Indication
Detection of Barrett's Esophagus and associated dysplasia in at-risk patients (e.g., chronic GERD)
Phase
Commercial
Status
Active, Commercially Available
Company
About Lucid Diagnostics
Lucid Diagnostics is a publicly traded company (NASDAQ: LUCD) dedicated to preventing cancer deaths through early detection. Its core mission is to address the unmet need in screening for Barrett's Esophagus, the pre-cancerous condition leading to esophageal adenocarcinoma (EAC), a lethal cancer with rapidly increasing incidence. The company's integrated solution, EsoCheck and EsoGuard, provides a non-endoscopic, office-based method for targeted screening of at-risk patients, representing a significant advancement over the standard of care.
View full company profile